American College of Clinical Pharmacy
      Search      Cart

Immunology/Transplantation PRN Focus Session -- Antibody-Mediated Rejection: Are We Really Making Progress? – A Spirited Debate

Saturday, October 07, 2017 from 1:45 PM to 3:15 PM MST at Phoenix Convention Center North Building Street Level: Meeting Room 122

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-17-136-L01-P
Activity Type: A Knowledge-Based Activity

Novel End Points for Measuring the Effectiveness of Antibody-Mediated Rejection
1:45 PM

  • Matthew J. Everly, Pharm.D., BCPSSpeaker: Matthew J. Everly, Pharm.D., BCPS
    Director, Terasaki Research Institute, Los Angeles and Adjunct Assistant Professor of Medicine, Nephrology Division, David Geffen School of Medicine, University of California
      View Biography

Learning Objectives
1. Define AMR in various solid organ transplant populations.
2. Discuss the limitations of current clinical endpoints for AMR.
3. Analyze the literature behind novel clinical endpoints for AMR treatment.
4. Describe early phase investigational treatments for AMR.
Antibody-Mediated Rejection: Yes, Novel Agents Are Worthy of Use -- Pro Point and Rebuttal
2:00 PM

  • Christopher R. Ensor, Pharm.D., FAST, BCPSSpeaker: Christopher R. Ensor, Pharm.D., FAST, BCPS
    Assistant Professor, Pharmacy and Therapeutics; Clinical Faculty, Thoracic Transplantation; Co-Director, Pharmacotherapy Scholars Program, University of Pittsburgh, Pennsylvania

Learning Objectives
1. Describe current and novel agents and treatment regimens for AMR.
2. Compare the costs, effectiveness, and risk associated with each agent/regimen used in AMR treatment based upon the point-counterpoint debate.
3. Design a treatment regimen, using the specifics of your institution, transplant population, and ability to take risk based upon the point-counterpoint debate.
Antibody-Mediated Rejection: No, the Risks and Costs of Novel Agents Outweigh Their Benefit -- Con Counterpoint and Rebuttal
2:30 PM

  • Lisa Potter, Pharm.D., FCCP, BCPSSpeaker: Lisa Potter, Pharm.D., FCCP, BCPS
    Clinical Coordinator, Transplant Pharmacy Services, University of Chicago Medicine, Chicago, Illinois
      View Biography

AMR Expert Panel Discussion
2:55 PM

  • Speaker: Steven Gabardi, Pharm.D., FCCP, BCPS
    Abdominal Organ Transplant Specialist, Program Director, PGY2 Organ Transplant Pharmacology Residency, Brigham and Women's Hospital, Department of Transplant Surgery/Renal Division; Assistant Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Learning Objectives
1. Review key AMR debate points.
2. Justify costs associated with AMR consequences and therapeutics.
3. Describe future direction of AMR therapies.